Please use this identifier to cite or link to this item: https://doi.org/10.1182/blood-2010-04-281600
DC FieldValue
dc.titleC/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations
dc.contributor.authorPulikkan, J.A.
dc.contributor.authorPeramangalam, P.S.
dc.contributor.authorDengler, V.
dc.contributor.authorHo, P.A.
dc.contributor.authorPreudhomme, C.
dc.contributor.authorMeshinchi, S.
dc.contributor.authorChristopeit, M.
dc.contributor.authorNibourel, O.
dc.contributor.authorMüller-Tidow, C.
dc.contributor.authorBohlander, S.K.
dc.contributor.authorTenen, D.G.
dc.contributor.authorBehre, G.
dc.date.accessioned2016-07-08T09:26:02Z
dc.date.available2016-07-08T09:26:02Z
dc.date.issued2010-12-16
dc.identifier.citationPulikkan, J.A., Peramangalam, P.S., Dengler, V., Ho, P.A., Preudhomme, C., Meshinchi, S., Christopeit, M., Nibourel, O., Müller-Tidow, C., Bohlander, S.K., Tenen, D.G., Behre, G. (2010-12-16). C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood 116 (25) : 5638-5649. ScholarBank@NUS Repository. https://doi.org/10.1182/blood-2010-04-281600
dc.identifier.issn00064971
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/125363
dc.description.abstractThe transcription factor, CCAAT enhancer binding protein alpha (C/EBPα), is crucial for granulopoiesis and is deregulated by various mechanisms in acute myeloid leukemia (AML). Mutations in the CEBPA gene are reported in 10% of human patients with AML. Even though the C/EBPα mutants are known to display distinct biologic function during leukemogenesis, the molecular basis for this subtype of AML remains elusive.We have recently showed the significance of deregulation of C/EBPα-regulated microRNA (miR) in AML. In this study, we report that miR-34a is a novel target of C/EBPα in granulopoiesis. During granulopoiesis, miR-34a targets E2F3 and blocks myeloid cell proliferation. Analysis of AML samples with CEBPA mutations revealed a lower expression of miR-34a and elevated levels of E2F3 as well as E2F1, a transcriptional target of E2F3. Manipulation of miR-34a reprograms granulocytic differentiation of AML blast cells with CEBPA mutations. These results define miR-34a as a novel therapeutic target in AML with CEBPA mutations. © 2010 by The American Society of Hematology.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1182/blood-2010-04-281600
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1182/blood-2010-04-281600
dc.description.sourcetitleBlood
dc.description.volume116
dc.description.issue25
dc.description.page5638-5649
dc.description.codenBLOOA
dc.identifier.isiut000285383900028
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.